Welcure Drugs & Pharmaceuticals Ltd
Welcure Drugs & Pharmaceuticals Ltd (WELCURE) last reported results for the quarter ended Mar 2026, with sales of ₹0 crore and net profit of ₹-50 crore. The stock last traded at ₹0.21, a market capitalisation of ₹26 crore. Over the past 52 weeks the stock has ranged between ₹0.19 and ₹0.81. Figures are as of 6 Oct 2026 and are not real time.
Welcure Drugs & Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹0.21
- Market cap
- ₹26 cr
- Book value
- ₹0.78
- ROE
- -5.50%
- ROCE
- -3.40%
- Dividend yield
- 0.00%
- 52w high / low
- 0.81/0.19
Metrics as of 6 Oct 2026. Not real time.
Track Welcure Drugs & Pharmaceuticals Ltd
Cruxal reads every Welcure Drugs & Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Welcure Drugs & Pharmaceuticals Ltd growth and returns
- 10 Years
- 127%
- 5 Years
- 390%
- 3 Years
- %
- TTM
- 1389%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -353%
- 10 Years
- -2%
- 5 Years
- -25%
- 3 Years
- -18%
- 1 Year
- -66%
- 10 Years
- -2%
- 5 Years
- -2%
- 3 Years
- -2%
- Last Year
- -6%
Welcure Drugs & Pharmaceuticals Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹0 cr, down 100.0% from ₹21 cr a year earlier. Net profit swung to a loss of ₹50 cr.
| ₹ crore | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 25 | 1 | 21 | 300 | 66 | 0 | 0 |
| Expenses | 0 | 23 | 1 | 21 | 269 | 54 | 0 | 50 |
| Operating profit | -0 | 2 | 0 | 1 | 31 | 11 | -0 | -50 |
| OPM % | — | 7% | 10% | 3.0% | 10% | 17% | — | — |
| Other income | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0 | 2 | 0 | 3 | 31 | 11 | 1 | -50 |
| Tax % | 0% | 0% | 56% | 0% | 25% | 25% | 25% | 0% |
| Net profit | -0 | 2 | 0 | 3 | 23 | 8 | 1 | -50 |
| EPS (₹) | -0.02 | 0.01 | 0.00 | 0.02 | 0.19 | 0.07 | 0.01 | -0.40 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Welcure Drugs & Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 366 |
| Operating profit | 0 | -0 | 0 | -0 | 0 | 0 | -0 | -0 | 1 | -7 |
| OPM % | 33% | -40% | 0.0% | -12% | 46% | 18% | — | — | 4.0% | -1.9% |
| Net profit | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | 2 | -5 |
| EPS (₹) | 0.00 | -0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.01 | -0.01 | 0.02 | -0.04 |
TTM is the trailing twelve months to the most recent quarter.
Welcure Drugs & Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 12 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 112 | 124 |
| Reserves | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -12 | -10 | -27 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 123 | 0 |
| Other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 | 413 |
| Total liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 267 | 510 |
| Fixed assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other assets | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 267 | 509 |
| Total assets | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 267 | 510 |
As reported by the company. Total assets equal total liabilities by construction.
Welcure Drugs & Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -222 | 2 |
| Cash from investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -1 |
| Cash from financing | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 222 | 0 |
| Net cash flow | 0 | -0 | 0 | -0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Free cash flow | 0 | -0 | 0 | -0 | 0 | 0 | 0 | -0 | -222 | 2 |
| CFO / operating profit | 67% | 50% | — | 100% | 67% | 100% | -79% | 57% | -22,890% | -25% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Welcure Drugs & Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 120% | -67% | 0% | -40% | 133% | 25% | 10% | -13% | 3% | -3% |
| Debtor days | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 282 | 213 |
| Inventory days | — | — | — | — | — | — | — | — | 2,554 | 162 |
| Days payable | — | — | — | — | — | — | — | — | 52 | 226 |
| Cash conversion cycle | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 2,784 | 150 |
| Working capital days | 81 | 73 | 46 | 0 | 0 | 0 | — | — | 2,092 | -56 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Welcure Drugs & Pharmaceuticals Ltd shareholding pattern
| % held | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Public | 100.00% | 100.00% | 100.00% | 99.98% | 99.99% | 99.99% | 100.00% | 100.00% |
| No. of shareholders | 31,045 | 30,218 | 30,605 | 32,366 | 37,298 | 76,954 | 87,288 | 87,977 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.